#251 - AMA #46: Optimizing brain health: Alzheimer's disease risk factors, APOE, prevention strategies, and more

Apr 17, 2023 Episode Page ↗
Overview

Peter Attia and Nick Stenson discuss brain health, Alzheimer's diagnosis, and neurodegeneration in this AMA. They cover APOE gene variants, blood-based biomarkers, and the significant impact of modifiable behaviors and lifestyle factors on reducing disease risk.

At a Glance
6 Insights
34m 17s Duration
7 Topics
5 Concepts

Deep Dive Analysis

Introduction to Brain Health and Alzheimer's Disease

Clinical Diagnosis of Alzheimer's Disease

Biomarkers for Alzheimer's Disease Diagnosis

Genetic Component of Alzheimer's Disease Risk

Understanding APOE Gene Variants and Combinations

Prevalence of Alzheimer's Disease and Genetic Risk

Impact of Modifiable Behaviors on Alzheimer's Risk Reduction

Clinical Diagnosis of Alzheimer's

This diagnosis is typically made by neurologists who assess various symptoms like memory difficulty, confusion, and language problems. It also involves mental status exams, neuropsychological tests, and lab tests to rule out other conditions like hypothyroidism or vitamin deficiencies. A definitive diagnosis traditionally requires an autopsy, though modern biomarkers are improving accuracy.

C2N Test

A blood-based biomarker test that predicts the probability of Alzheimer's disease pathology. It combines a patient's APOE gene variant, the ratio of amyloid beta 42 to amyloid beta 40 measured in plasma, and the patient's age. This test is primarily used in high-risk patients to help assess risk and potentially monitor the impact of interventions.

Deterministic Genes (AD)

These are three highly penetrant genes—PSEN1, PSEN2, and APP—for which if a person has the gene, they are highly likely to develop Alzheimer's disease. These genes are very uncommon, collectively accounting for only about 1% of Alzheimer's cases, and typically lead to early-onset disease, often in a person's 50s.

APOE Gene Alleles

The APOE gene has three common variants or alleles: E2, E3, and E4. E3 is the most common, followed by E4, with E2 being the rarest. Individuals inherit one copy from each parent, leading to six possible combinations (e.g., 33, 34, 44), which influence an individual's risk of developing Alzheimer's disease.

Healthy Lifestyle Factors (AD Prevention)

These encompass behaviors such as not smoking, getting adequate sleep, engaging in regular exercise, and maintaining good nutrition. Epidemiological studies suggest that consistently engaging in multiple healthy lifestyle factors can significantly reduce the rate of cognitive decline and offset much of the risk associated with genetic predispositions like the APOE4 gene.

?
How is Alzheimer's disease diagnosed?

Alzheimer's disease is primarily diagnosed clinically by neurologists who assess symptoms, conduct mental status exams, and perform lab tests to rule out other causes. While a definitive diagnosis has historically required an autopsy, blood-based biomarkers and imaging are increasingly used to confirm pathology.

?
Are there biomarkers for Alzheimer's disease similar to ApoB for cardiovascular disease?

Alzheimer's disease is more complicated than cardiovascular disease in this regard, and there isn't a single, neat biomarker like ApoB. However, tests like the C2N score, which uses APOE status, amyloid beta ratios, and age, can predict the probability of AD pathology, though it's still in early stages of clinical use.

?
What do genetic test results mean for someone's long-term risk of developing Alzheimer's disease or dementia?

There are rare deterministic genes (PSEN1, PSEN2, APP) that almost guarantee early-onset AD. For the vast majority, the APOE4 gene is a strong risk factor, with two-thirds of AD cases having at least one copy, but it is not deterministic. Other genes can amplify or attenuate this risk, and healthy behaviors can significantly modify it.

?
What are the different APOE gene combinations a person can have?

A person inherits one APOE allele (E2, E3, or E4) from each parent, leading to six possible combinations: 2/2, 2/3, 3/3, 2/4, 3/4, and 4/4. The 3/3 genotype is the most common, while 4/4 is the second rarest and carries the highest risk for Alzheimer's.

?
Why is it important for everyone to know their APOE status?

Knowing one's APOE status is important because while it's not deterministic for Alzheimer's, it indicates a genetic predisposition that can be influenced by lifestyle. Peter Attia believes there's a lot that can be done to delay onset and/or reduce risk, making this knowledge actionable for prevention strategies.

?
Can the risk of Alzheimer's disease be decreased with behavioral changes?

Yes, epidemiological data, such as the Chicago Health and Aging Project, suggest that engaging in healthy lifestyle factors (e.g., not smoking, good sleep, exercise, nutrition) can significantly reduce the rate of cognitive decline and offset much of the risk, especially for individuals with the APOE4 gene.

1. Adopt Healthy Lifestyle Factors

Engage in multiple healthy lifestyle factors, including not smoking, getting good sleep, exercising, and maintaining good nutrition. These behaviors can significantly offset the risk of cognitive decline, with a greater impact observed in individuals with ApoE4 variants.

2. Know Your ApoE Gene Status

Determine your ApoE gene status through testing. This knowledge is important because it empowers individuals to take actionable steps to potentially delay the onset or reduce the risk of Alzheimer’s disease.

3. Prioritize Regular Exercise

Incorporate regular exercise into your routine. The evidence is overwhelming that exercise is beneficial for brain health and preventing neurodegeneration, making it a ’no regret move'.

4. Rule Out Treatable Causes of Cognitive Decline

If experiencing symptoms of cognitive decline (e.g., memory difficulty, confusion), undergo lab tests to rule out other treatable conditions. Profound hypothyroidism or B12/B6 deficiencies can present with symptoms similar to Alzheimer’s disease.

5. Consider Comprehensive Genetic Testing

For a more thorough assessment of Alzheimer’s risk beyond ApoE4, consider whole genome sequencing. This method offers a lower error rate and identifies a broader suite of relevant genes compared to commercial snip tests.

6. Utilize C2N Score for High-Risk Patients

For individuals identified as very high risk for Alzheimer’s disease, consider using the C2N amyloid score. This plasma-based biomarker provides additional risk information and can potentially track the impact of interventions on amyloid beta ratios, though its use is still in early days.

anyone with a brain regardless of their apo e genotype or family history is at risk

Peter Attia (paraphrasing Richard Isaacson)

I do believe there's a lot that can be done to delay onset and or reduce risk

Peter Attia

healthy behaviors have a greater impact on e4s than non e4s

Peter Attia
1%
Percentage of Alzheimer's disease cases accounted for by deterministic genes (PSEN1, PSEN2, APP) These genes typically lead to very early-onset Alzheimer's.
2/3
Proportion of Alzheimer's disease patients (without deterministic genes) who have at least one copy of the APOE4 gene This highlights the strong association of APOE4 with AD risk.
25%
Percentage of the general population with at least one copy of the APOE4 gene Most of these individuals have only one copy.
2%
Percentage of the general population with two copies of the APOE4 gene (APOE 4/4) This is a relatively rare genotype but carries the highest genetic risk for AD.
2:1
Global prevalence ratio of Alzheimer's disease in women to men Women are twice as likely to get AD as men, attributed to individual risk factors and longer lifespan.
50-55%
Approximate percentage of the population with the APOE 3/3 genotype This is considered the baseline or most common genotype.
25%
Approximate percentage of the population with the APOE 3/4 genotype This is the next most common genotype after 3/3.
15 to 20 years
Duration of follow-up for the Chicago Health and Aging Project study The study followed nearly 4,000 individuals aged 65 and older.